

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-103 (Cancelled).

104 (Currently Amended). A polypeptide ~~capable of binding~~that binds to NIK, ~~comprising~~consisting of:

(a) the intracellular domain of cyc (residues 284-369 SEQ ID NO: 22);

(b) a fragment of (a) that retains the ability to bind NIK;

(c) a variant of (a) or (b) maintaining at least ~~90%~~95% identity with a) or b) and retaining the ability to bind NIK; or

(d) a salt or functional derivative of (a), (b) or (c) that retains the ability to bind NIK, ~~or~~ said functional derivative being an ester or aliphatic amide of the carboxyl group of the polypeptide or an N-acyl derivative of a free amino group of the polypeptide, or an O-acyl derivative of a free hydroxyl group of the polypeptide.

~~—————(e) a circularly permuted derivative of (a), (b) or (c) that retains the ability to bind NIK,~~

~~wherein said polypeptide contains no more of the
sequence of eye (SEQ ID NO: 22) than the intracellular domain
thereof (residues 284-369 of SEQ ID NO: 22).~~

105 (Previously Presented). A polypeptide in
accordance with claim 104, comprising 41MDD (residues 329-369
of SEQ ID NO: 22).

106 (Previously Presented). A polypeptide in
accordance with claim 104, comprising ICDcyc (residues 284-369
of SEQ ID NO: 22).

107 (Previously Presented). A polypeptide in
accordance with claim 104, comprising the polypeptide of
residues 289-369 of SEQ ID NO: 22.

108 (Previously Presented). A polypeptide in
accordance with claim 104, comprising the polypeptide of SEQ
ID NO: 23.

109 (Previously Presented). A polypeptide in
accordance with claim 104, comprising the polypeptide of SEQ
ID NO: 25.

110 (Previously Presented). A polypeptide in
accordance with claim 104, comprising the polypeptide of SEQ
ID NO: 26.

111 (Previously Presented). A polypeptide in
accordance with claim 104, comprising the polypeptide of SEQ
ID NO: 27.

112 (Withdrawn). A DNA encoding a polypeptide in accordance with claim 104.

113 (Withdrawn). A vector comprising the DNA in accordance with claim 112.

114 (Withdrawn). A cell comprising a vector in accordance with claim 113.

115 (Withdrawn). A method for the production of a polypeptide capable of binding to NIK, comprising culturing a cell according to claim 114 and collecting the polypeptide produced.

116 (Withdrawn). An antibody that specifically recognizes an epitope within the intracellular domain of cyc (residues 284-369 of SEQ ID NO: 22), or an epitope-binding fragment thereof.

117 (Withdrawn). An antibody or fragment thereof in accordance with claim 116, capable of inhibiting the binding of cyc to NIK.

118 (Withdrawn). An antibody or fragment thereof in accordance with claim 116, that specifically recognizes an epitope within the sequence of 41MDD (residues 329-369 of SEQ ID NO: 22).

119 (Withdrawn). An antibody or fragment thereof in accordance with claim 116, wherein said antibody comprises a

Appln. No. 10/511,722

Amdt. dated August 20, 2007

Reply to Office action of February 20, 2007

monoclonal or polyclonal chimeric, fully-humanized, or anti-
anti-Id antibody, or an intrabody.